Blood-stage malaria vaccines — recent progress and future challenges

References

• Abdulla, S., Oberholzer, R, Juma, O., Kubhoja, S., Machera, F., Membi, C., Oman, S., Urassa, A., Mshinda, H., Jumanne, A., Salim, N., Shomari, M., Aebi, T., Schellenberg, D. M., Carter, T., Villafana, T., Demoitié, M.-A., Dubois, M.-C., Leach, A., Lievens, M., Vekemans, J., Cohen, J., Ballou, W. R. & Tanner, M. (2008). Safety and immunogenicity of RTS,S/ASO2D malaria vaccine in infants. New England Journal of Medicine, 359, 2533–2544.
   PubMed Web of Science ®Google Scholar
• Alonso, P. L., Sacarlal, J., Aponte, J. J., Leach, A., Macete, E., Milman, J., Mandomando, I., Spiessens, B., Guinovart, C., Espasa, M., Bassat, Q., Aide, P., Ofori-Anyinam, O., Navia, M. M., Corachan, S., Ceuppens, M., Dubois, M.-C., Demoitié, M.-A., Dubovsky, F., Menendez, C., Tomieporth, N., Ballou, W. R., Thompson, R. & Cohen, J. (2004). Efficacy of the RTS,S/ASO2A vaccine against Plasmodium falciparum infection and disease in young African children: randomised controlled trial. Lancet, 364, 1411–1420.
   PubMed Web of Science ®Google Scholar
• Alonso, P. L., Sacarlal, J., Aponte, J. J., Leach, A., Macete, E., Aide, P., Sigauque, B., Milman, J., Mandomando, I., Bassat, Q., Guinovart, C., Espasa, M., Corachan, S., Lievens, M., Navia, M. M., Dubois, M.-C., Menendez, C., Dubovsky, F., Cohen, J., Thompson, R. & Ballou, W. R (2005). Duration of protection with RTS,S/ASO2A malaria vaccine in prevention of Plasmodium falciparum disease in Mozambican children: single-blind extended follow-up of a randomised controlled trial. Lancet, 366, 2012–2018.
   PubMed Web of Science ®Google Scholar
• Arévalo-Herrera, M., Chimis, C. & Herrera, S. (2010). Current status of Plasmodium vivax vaccine. Human Vaccines, in press.
   Google Scholar
• Atmar, R. L. & Keitel, W. A. (2009). Adjuvants for pandemic influenza vaccines. Current Topics in Microbiology and Immunology, 333, 323–344.
   PubMedGoogle Scholar
• Audran, R., Cachat, M., Lurati, F., Soe, S., Leroy, O., Corradin, G., Druilhe, P. & Spertini, F. (2005). Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen. Infection and Immunity, 73, 8017–8026.
   PubMed Web of Science ®Google Scholar
• Ballou, W. R. (2009). The development of the RTS,S malaria vaccine candidate: challenges and lessons. Parasite Immunology, 31, 492–500.
   PubMed Web of Science ®Google Scholar
• Ballou, W. R., Arevalo-Herrera, M., Carucci, D., Richie, T. L., Corradin, G., Diggs, C., Druilhe, P., Giersing, B. K., Saul, A., Heppner, D. G., Kester, K. E., Lanar, D. E., Lyon, J., Hill, A. V. S., Pan, W. & Cohen, J. D. (2004). Update on the clinical devel-opment of candidate malaria vaccines. American Journal of Tropical Medicine and Hygiene, 71, 239–247.
   PubMed Web of Science ®Google Scholar
• Bejon, P., Andrews, L., Andersen, R. F., Dunachie, S., Webster, D., Walther, M., Gilbert, S. C., Peto, T. & Hill, A. V. S. (2005). Calculation of liver-to-blood inocula, parasite growth rates, and preerythrocytic vaccine efficacy, from serial quantitative polymerase chain reaction studies of volunteers challenged with malaria sporozoites. Journal of Infectious Diseases, 191, 619–626.
   PubMed Web of Science ®Google Scholar
• Bejon, P., Lusingu, J., Olotu, A., Leach, A., Lievens, M., Vekemans, J., Mshamu, S., Lang, T., Gould, J., Dubois, M.-C., Demoitié, M.-A., Stallaert, J.-F., Vansadia, P., Carter, T., Njuguna, P., Awuondo, K. O., Malabeja, A., Abdul, O., Gesase, S., Mturi, N., Drakeley, C. J., Savarese, B., Villafana, T., Ballou, W. R, Cohen, J., Riley, E. M., Lemnge, M. M., Marsh, K. & von Seidlein, L. (2008). Efficacy of RTS,S/ASO lE vaccine against malaria in children 5 to 17 months of age. New England Journal of Medicine, 359, 2521–2532.
   PubMed Web of Science ®Google Scholar
• Belnoue, E., Voza, T., Costa, F. T. M., Grüner, A. C., Mauduit, M., Rosa, D. S., Depinay, N., Kayibanda, M., Vigário, A. M., Mazier, D., Snounou, G., Sinnis, P. & Renia, L. (2008). Vaccination with live Plasmodium yoelii blood stage parasites under chloroquine cover induces cross-stage immunity against malaria liver stage. Journal of Immunology, 181, 8552–8558.
   PubMed Web of Science ®Google Scholar
• Bergmann-Leitner, E. S., Duncan, E. H., Mullen, G. E., Burge, J. R., Khan, F., Long, C. A., Angov, E. & Lyon, J. A. (2006). Critical evaluation of different methods for measuring the functional activity of antibodies against malaria blood stage antigens. American Journal of Tropical Medicine and Hygiene, 75,437–442.
   PubMed Web of Science ®Google Scholar
• Blanchard Rohner, G., Snape, M. D., Kelly, D. F., John, T., Morant, A., Yu, L.-M., Borkowski, A., Ceddia, F., Borrow, R, Siegrist, C.-A. & Pollard, A. J. (2008). The magnitude of the antibody and memory B cell responses during priming with a protein-polysaccharide conjugate vaccine in human infants is associated with the persistence of antibody and the intensity of booster response. Journal of Immunology, 180, 2165–2173.
   PubMed Web of Science ®Google Scholar
• Bouharoun-Tayoun, H., Attanath, P., Sabchareon, A., Chongsuphajaisiddhi, T. & Druilhe, P. (1990). Antibodies that protect humans against Plasmodium falciparum blood stages do not on their own inhibit parasite growth and invasion in vitro, but act in cooperation with monocytes. Journal of Experimental Medicine, 172,1633–1641.
   PubMed Web of Science ®Google Scholar
• Bull, P. C., Lowe, B. S., Kortok, M., Molyneux, C. S., Newbold, C. I. & Marsh, K. (1998). Parasite antigens on the infected red cell surface are targets for naturally acquired immunity to malaria. Nature Medicine, 4,358–360.
   PubMed Web of Science ®Google Scholar
• Butler, D. (2009). Initiative targets malaria eradication. Nature, 462, 19.
   PubMed Web of Science ®Google Scholar
• Carvalho, L. J. M., Alves, F. A., Bianco, C. Jr, Oliveira, S. G., Zanini, G. M., Soe, S., Druilhe, P., Theisen, M., Muniz, J. A. P. C. & Daniel-Ribeiro, C. T. (2005). Immunization of Saimiri sciureus monkeys with a recombinant hybrid protein derived from the Plasmodium falciparum antigen glutamate-rich protein and merozoite surface protein 3 can induce partial protection with Freund and Montanide I5A720 adjuvants. Clinical and Diagnostic Laboratory Immunology, 12,242-248.
   Google Scholar
• Chowdhury, D. R, Angov, E., Kariuld, T. & Kumar, N. (2009). A potent malaria transmission blocking vaccine based on codon harmonized full length Pfs48/45 expressed in Escherichia coli. PLoS One, 4, e6352.
   PubMed Web of Science ®Google Scholar
• Coler, R. N., Carter, D., Friede, M. & Reed, S. G. (2009). Adjuvants for malaria vaccines. Parasite Immunology, 31, 520–528.
   PubMed Web of Science ®Google Scholar
• Coppel, R. L. (2009). Vaccinating with the genome: a Sisyphean task? Trends in Parasitology, 25,205–212.
   PubMed Web of Science ®Google Scholar
• Crompton, P. D., Mircetic, M., Weiss, G., Baughman, A., Huang, C.-Y., Topham, D. J., Treanor, J. J., Sanz, I., Lee, F. E.-H., Durbin, A. P., Miura, K., Narum, D. L., Ellis, R. D., Malkin, E., Mullen, G. E. D., Miller, L. H., Martin, L. B. & Pierce, S. K. (2009). The TLR9 ligand CpG promotes the acquisition of Plasmodium falciparum-specific memory B cells in malaria-naive individuals. Journal of Immunology, 182, 3318-3326.
   Google Scholar
• Crompton, P. D., Miura, K., Traore, B., Kayentao, K., Ongoiba, A., Weiss, G., Doumbo, S., Doumtabe, D., Kone, Y., Huang, C. Y., Doumbo, O. K., Miller, L. H., Long, C. A. & Pierce, S. K. (2010). In vitro growth-inhibitory activity and malaria risk in a cohort study in Mali. Infection and Immunity, 78, 737-745.
   Google Scholar
• De Koning-Ward, T. F., O'Donnell, R. A., Drew, D. R., Thomson, R., Speed, T. P. & Crabb, B. S. (2003). A new rodent model to assess blood stage immunity to the Plasmodium falciparum antigen merozoite surface protein 119 reveals a protective role for invasion inhibitory antibodies. Journal of Immunology, 198, 869–875.
   Google Scholar
• Dicko, A., Diemert, D. J., Sagara, I., Sogoba, M., Niambele, M. B., Assadou, M. H., Guindo, O., Kamate, B., Baby, M., Sissoko, M., Malkin, E. M., Fay, M. P., Thera, M. A., Miura, K., Dolo, A., Diallo, D. A., Mullen, G. E., Long, C. A., Saul, A., Doumbo, O. & Miller, L. H. (2007). Impact of a Plasmodium falciparum AMA1 vaccine on antibody responses in adult Malians. PLoS One, 2, e1045. Dicko, A., Sagara, I., Ellis, R. D., Miura, K., Guindo, O., Kamate, B., Sogoba, M., Niambele, M. B., Sissoko, M., Baby, M., Dolo, A., Mullen, G. E., Fay, M. P., Pierce, M., Diallo, D. A., Saul, A., Miller, L. H. & Doumbo, O. K. (2008). Phase 1 study of a combination AMA1 blood stage malaria vaccine in Malian children. PLoS One, 3, el 563.
   Google Scholar
• Dodoo, D., Aikins, A., Kusi, K. A., Lamptey, H., Remarque, E., Milligan, P., Bosomprah, S., Chilengi, R., Osei, Y. D., Akanmori, B. D. & Theisen, M. (2008). Cohort study of the association of antibody levels to AMA1, MSP119, MSP3 and GLURP with protection from clinical malaria in Ghanaian children. Malaria Journal, 7,142.
   Google Scholar
• Doolan, D. L., Southwood, S., Freilich, D. A., Sidney, J., Graber, N. L., Shamey, L., Bebris, L., Florens, L., Dobano, C., Wimey, A. A., Appella, E., Hoffman, S. L., Yates III, J. R., Carucci, D. J. & Sette, A. (2003). Identification of Plasmodium falciparum antigens by antigenic analysis of genomic and proteomic data. Proceedings of the National Academy of Sciences of the United States of America, 100, 9952–9957.
   PubMed Web of Science ®Google Scholar
• Doolan, D. L., Mu, Y., Unal, B., Sundaresh, S., Hirst, S., Valdez, C., Randall, A., Molina, D., Liang, X., Freilich, D. A., Oloo, J. A., Blair, P. L., Aguiar, J. C., Baldi, P., Davies, D. H. & Feigner, P. L (2008). Profiling humoral immune responses to P. falciparum infec-tion with protein micmarrays. Aroteomks, 8, 4680–4694.
   Google Scholar
• Dorfman, J. R., Bejon, P., Ndungu, F. M., Langhorne, J., Kortok, M. M., Lowe, B. S., Mwangi, T. W., Williams, T. N. & Marsh, K. (2005). B cell memory to 3 Plasmodium falciparum blood-stage antigens in a malaria-endemic area. Journal of Infectious Diseases, 191, 1623–1630.
   PubMed Web of Science ®Google Scholar
• Draper, S. J. & Heeney, J. L. (2010). Viruses as vaccine vectors for infectious diseases and cancer. Nature Reviews, Microbiology, 8, 62–73.
   PubMed Web of Science ®Google Scholar
• Draper, S. J., Moore, A. C., Goodman, A. L., Long, C. A., Holder, A. A., Gilbert, S. C., Hill, F. & Hill, A. V. S. (2008). Effective induction of high-titer antibodies by viral vector vaccines. Nature Medicine, 14, 819–821.
   PubMed Web of Science ®Google Scholar
• Draper, S. J., Goodman, A. L., Biswas, S., Forbes, E. K., Moore, A. C., Gilbert, S. C. & Hill, A. V. S. (2009). Recombinant viral vaccines expressing mer-ozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria. Cell Host and Microbe, 5,95–105.
   PubMed Web of Science ®Google Scholar
• Dunachie, S. J., Walther, M., Epstein, J. E., Keating, S., Berthoud, T., Andrews, L., Andersen, R. F., Bejon, P., Goonetilleke, N., Poulton, I., Webster, D. P., Butcher, G., Watkins, K., Sinden, R. E., Levine, G. L., Richie, T. L., Schneider, J., Kaslow, D., Gilbert, S. C., Carucci, D. J. & Hill, A. V. S. (2006). A DNA prime-modified vaccinia virus Ankara boost vaccine encoding thrombospondin-related adhesion protein but not circumsporozoite protein partially protects healthy malaria-naive adults against Plasmodium falciparum sporozoite challenge. Infection and Immunity, 74,5933–5942.
   PubMed Web of Science ®Google Scholar
• Dutta, S., Haynes, J. D., Barbosa, A., Ware, L. A., Snavely, J. D., Moch, J. K., Thomas, A. W. & Lanar, D. E. (2005). Mode of action of invasion-inhibitory antibodies directed against apical membrane antigen 1 of Plasmodium falciparum. Infection and Immunity, 73,2116–2122.
   PubMed Web of Science ®Google Scholar
• Dutta, S., Sullivan, J. S., Grady, K. K., Haynes, J. D., Komisar, J., Batchelor, A. H., Soisson, L., Diggs, C. L., Heppner, D. G., Lanar, D. E., Collins, W. E. & Barnwell, J. W. (2009). High antibody titer against apical membrane antigen-1 is required to protect against malaria in the Aotus model. PLoS One, 4, e8138.
   Google Scholar
• Edstein, M. D., Kotecka, B. M., Anderson, K. L., Pombo, D. J., Kyle, D. E., Rieckmann, K. H. & Good, M. F. (2005). Lengthy antimalarial activity of atovaquone in human plasma following atovaquone—proguanil administration. Antimicrobial Agents and Chemotherapy, 49, 4421-4422.
   Google Scholar
• Egan, A., Waterfall, M., Pinder, M., Holder, A. & Riley, E. (1997). Characterization of human T- and B-cell epitopes in the C terminus of Plasmodium falciparum merozoite surface protein 1: evidence for poor T-cell recognition of polypeptides with numer-ous disulfide bonds. Infection and Immunity, 65, 3024–3031.
   PubMed Web of Science ®Google Scholar
• Ellis, R D., Mullen, G. E. D., Pierce, M., Martin, L. B., Miura, K., Fay, M. P., Long, C. A., Shaffer, D., Saul, A., Miller, L. H. & Durbin, A. P. (2009). A Phase 1 study of the blood-stage malaria vaccine candidate AMA1 -Cl/Alhydrogel with CPG 7909, using two different formulations and dosing intervals. Vaccine, 27,4104-4109.
   Google Scholar
• Ellis, R. D., Martin, L. B., Shaffer, D., Long, C. A., Miura, K., Fay, M. P., Narum, D. L., Zhu, D., Mullen, G. E. D., Mahanty, S., Miller, L. H. & Durbin, A. P. (2010). Phase 1 trial of the Plasmodium falciparum blood stage vaccine MSP1(42)-C1/ Alhydrogel with and without CPG 7909 in malaria naive adults. PLoS One, 5, e8787.
   Google Scholar
• Esen, M., Kremsner, P. G., Schleucher, R., Gassler, M., Imoukhuede, E. B., Imbault, N., Leroy, O., Jepsen, S., Knudsen, B. W., Schumm, M., Knobloch, J., Theisen, M. & Mordmiiller, B. (2009). Safety and immunogenicity of GMZ2 — a MSP3—GLURP fusion protein malaria vaccine can-didate. Vaccine, 27,6862-6868.
   Google Scholar
• Faber, B. W., Remarque, E. J., Morgan, W. D., Kocken, C. H. M., Holder, A. A. & Thomas, A. W. (2007). Malaria vaccine-related benefits of a single protein comprising Plasmodium falciparum apical membrane antigen 1 domains I and II fused to a modified form of the 19-kilodalton C-terminal fragment of merozoite surface protein 1. Infection and Immunity, 75,5947-5955.
   Google Scholar
• Fleit, H. B. & Kobasiuk, C. D. (1991). The human monocyte-like cell line THP-1 expresses Fc gamma RI and Fc gamma RII. Journal of Leukocyte Biology, 49, 556-565.
   Google Scholar
• Freitas do Rosario, A. P., Muxel, S. M., Rodriguez-Malaga, S. M., Sardinha, L. R., Zago, C. A., Castillo-Mendez, S. I., Alvarez, J. M. & d'Imperio Lima, M. R (2008). Gradual decline in malaria-specific memory T cell responses leads to failure to maintain long-term protective immunity to Plasmodium chabaudi AS despite persistence of B cell memory and circulating antibody. Journal of Immunology, 181, 8344-8355.
   Google Scholar
• Gardner, M. J., Hall, N., Fung, E., White, O., Berriman, M., Hyman, R. W., Carlton, J. M., Pain, A., Nelson, K. E., Bowman, S., Paulsen, I. T., James, K., Eisen, J. A., Rutherford, K., Salzberg, S. L., Craig, A., Kyes, S., Chan, M.-S., Nene, V., Shallom, S. J., Suh, B., Peterson, J., Angiuoli, S., Pertea, M., Allen, J., Selengut, J., Haft, D., Mather, M. W., Vaidya, A. B., Martin, D. M., Fairlamb, A. H., Fraunholz, M. J., Roos, D. S., Ralph, S. A., McFadden, G. I., Cummings, L. M., Subramanian, G. M., Mungall, C., Venter, J. C., Carucci, D. J., Hoffman, S. L., Newbold, C., Davis, R. W., Fraser, C. M. & Barrell, B. (2002). Genome sequence of the human malaria parasite Plasmodium falciparum. Nature, 419, 498-511.
   Google Scholar
• Genton, B., Al-Yaman, F., Anders, R., Saul, A., Brown, G., Pye, D., Irving, D. O., Briggs, W. R., Mai, A., Ginny, M., Adiguma, T., Rare, L., Giddy, A., Reber-Liske, R., Stuerchler, D. & Alpers, M. P. (2000). Safety and immunogenicity of a three-component blood-stage malaria vaccine in adults living in an endemic area of Papua New Guinea. Vaccine, 18, 2504-2511.
   Google Scholar
• Genton, B., Betuela, I., Felger, I., Al-Yaman, F., Anders, R F., Saul, A., Rare, L., Baisor, M., Lorry, K., Brown, G. V., Pye, D., Irving, D. O., Smith, T. A., Beck, H.-P. & Alpers, M. P. (2002). A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a Phase 1-2b trial in Papua New Guinea. Journal of Infectious Diseases, 185, 820-827.
   Google Scholar
• Genton, B., Al-Yaman, F., Betuela, I., Anders, R. F., Saul, A., Baea, K., Mellombo, M., Taraika, J., Brown, G. V., Pye, D., Irving, D. O., Felger, I., Beck, H. P., Smith, T. A. & Alpers, M. P. (2003). Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children. Vaccine, 22,30–41.
   PubMed Web of Science ®Google Scholar
• Gikonyo, C., Bejon, P., Marsh, V. & Molyneux, S. (2008). Taking social relationships seriously: lessons learned from the informed consent practices of a vaccine trial on the Kenyan coast. Social Science and Medicine, 67, 708–720.
   PubMed Web of Science ®Google Scholar
• Graves, P. & Gelband, H. (2006). Vaccines for Preventing Malaria (S1f66). Cochrane Database of Systematic Reviews 2006. Art. No. CD005966. Chichester, U.K.: John Wiley & Sons.
   Google Scholar
• Hermsen, C. C., de Vlas, S. J., van Gemert, G. J., Telgt, D. S. C., Verhage, D. F. & Sauerwein, R W. (2004). Testing vaccines in human experimental malaria: statistical analysis of parasitemia measured by a quanti-tative real-time polymerase chain reaction. American Journal of Tropical Medicine and Hygiene, 71, 196–201.
   PubMed Web of Science ®Google Scholar
• Hill, A. V. S. (2006). Pre-erythrocytic malaria vaccines: towards greater efficacy. Nature Reviews, Immunology, 6,21–32.
   PubMed Web of Science ®Google Scholar
• Hill, A. V. S., Reyes-Sandoval, A., O'Hara, G., Ewer, K., Lawrie, A., Goodman, A., Nicosia, A., Folgori, A., Colloca, S., Cortese, R., Gilbert, S. C. & Draper, S. J. (2010). Prime-boost vectored malaria vaccines: progress and prospects. Human Vaccines, in press.
   Google Scholar
• Hirunpetcharat, C., Tian, J. H., Kaslow, D. C., van Rooijen, N., Kumar, S., Berzofsky, J. A., Miller, L. H. & Good, M. F. (1997). Complete protective immunity induced in mice by immunization with the 19-kilodalton carboxyl-terminal fragment of the merozoite surface protein-1 (MSP1[19]) of Plasmodium yoelii expressed in Saccharomyces cerevi-siae: correlation of protection with antigen-specific antibody titer, but not with effector CD4 + T cells. Journal of Immunology, 159, 3400–3411.
   PubMed Web of Science ®Google Scholar
• Holder, A. A. (2009). The carboxy-terminus of merozoite surface protein 1: structure, specific antibodies and immunity to malaria. Parasitology, 136, 1445–1456.
   PubMed Web of Science ®Google Scholar
• Hu, J., Chen, Z., Gu, J., Wan, M., Shen, Q., Kieny, M. P., He, J., Li, Z., Zhang, Q., Reed, Z. H., Zhu, Y., Li, W., Cao, Y., Qu, L., Cao, Z., Wang, Q., Liu, H., Pan, X., Huang, X., Zhang, D., Xue, X. & Pan, W. (2008). Safety and immunogenicity of a malaria vaccine, Plasmodium falciparum AMA-1/MSP-1 chi-meric protein formulated in montanide ISA 720 in healthy adults. PLoS One, 3, el 952.
   Google Scholar
• Huaman, M. C., Martin, L. B., Malkin, E., Narum, D. L., Miller, L. H., Mahanty, S. & Long, C. A. (2008). Ex vivo cytokine and memory T cell responses to the 42-kDa fragment of Plasmodium falciparum merozoite surface protein-1 in vaccinated volunteers. Journal of Immunology, 180, 1451–1461.
   PubMed Web of Science ®Google Scholar
• Hviid, L. (2010). The role of Plasmodium falciparum variant surface antigens in protective immunity and vaccine development. Human Vaccines, in press.
   Google Scholar
• Jafarshad, A., Dziegiel, M. H., Lundquist, R, Nielsen, L. K., Singh, S. & Druilhe, P. L. (2007). A novel antibody-dependent cellular cytotoxicity mechanism involved in defense against malaria requires costimu-lation of monocytes FcgammaRII and FcgammaRIII. Journal of Immunology, 178, 3099-3106.
   Google Scholar
• Jones, T. R., Narum, D. L., Gozalo, A. S., Aguiar, J., Fuhrmann, S. R., Liang, H., Haynes, J. D., Moch, J. K., Lucas, C., Luu, T., Magill, A. J., Hoffman, S. L. & Sim, B. K. L. (2001). Protection of Aotus monkeys by Plasmodium falciparum EBA-175 region II DNA prime-protein boost immunization regimen. Journal of Infectious Diseases, 183, 303–312.
   PubMed Web of Science ®Google Scholar
• Kawabata, Y., Udono, H., Honma, K., Ueda, M., Mukae, H., Kadota, J., Kohno, S. & Yui, K. (2002). Merozoite surface protein 1-specific immune response is protective against exoerythrocytic forms of Plasmodium yoelii. Infection and Immunity, 70, 6075–6082.
   PubMed Web of Science ®Google Scholar
• Keitel, W. A., Kester, K. E., Atmar, R. L., White, A. C., Bond, N. H., Holland, C. A., Krzych, U., Palmer, D. R., Egan, A., Diggs, C., Ballou, W. R., Hall, B. F. & Kaslow, D. (1999). Phase I trial of two recombinant vaccines containing the 19 kd carboxy terminal fragment of Plasmodium falciparum mero-zoite surface protein 1 (msp-1(19)) and T helper epitopes of tetanus toxoid. Vaccine, 18, 531-539.
   PubMed Web of Science ®Google Scholar
• Kleinschmidt, I., Schwabe, C., Benavente, L., Torrez, M., Ridl, F. C., Segura, J. L., Ehmer, P. & Nchama, G. N. (2009). Marked increase in child survival after four years of intensive malaria control. American Journal of Tropical Medicine and Hygiene, 80, 882-888.
   PubMed Web of Science ®Google Scholar
• Kumar, S., Yadava, A., Keister, D. B., Tian, J. H., Ohl, M., Perdue-Greenfield, K. A., Miller, L. H. & Kaslow, D. C. (1995). Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum mer-ozoite surface protein-1 in Aotus monkeys. Molecular Medicine, 1, 325-332.
   Google Scholar
• Kushwaha, A., Rao, P. P. L., Suresh, R. P. & Chauhan, V. S. (2001). Immunogenicity of recombinant frag-ments of Plasmodium falciparum acidic basic repeat antigen produced in Escherichia coli. Parasite Immunology, 23, 435–444.
   PubMed Web of Science ®Google Scholar
• Lawrence, G., Cheng, Q. Q., Reed, C., Taylor, D., Stowers, A., Cloonan, N., Rzepczyk, C., Smillie, A., Anderson, K., Pombo, D., Allworth, A., Eisen, D., Anders, R. & Saul, A. (2000). Effect of vaccination with 3 recombinant asexual-stage malaria antigens on initial growth rates of Plasmodium falciparum in non-immune volunteers. Vaccine, 18, 1925–1931.
   PubMed Web of Science ®Google Scholar
• Lengeler, C. (2004). Insecticide-treated Bed Nets and Curtains for Preventing Malaria. The Cochrane Database of Systematic Reviews 2004. Art. No. CD000363. Chichester, U.K.: John Wiley & Sons.
   Google Scholar
• Limbach, K. J. & Richie, T. L. (2009). Viral vectors in malaria vaccine development. Parasite Immunology, 31, 501-519.
   PubMed Web of Science ®Google Scholar
• Lopera-Mesa, T. M., Kushwaha, A., Mohmmed, A. & Chauhan, V. S. (2008). Plasmodium bergheimerozoite surface protein-9: immunogenicity and protective efficacy using a homologous challenge model. Vaccine, 26, 1335-1343.
   Google Scholar
• Lusingu, J. P., Gesase, S., Msham, S., Francis, F., Lemnge, M., Seth, M., Sembuche, S., Rutta, A., Minja, D., Segeja, M. D., Bosomprah, S., Cousens, S., Noor, R., Chilengi, R. & Druilhe, P. (2009). Satisfactory safety and immunogenicity of MSP3 malaria vaccine candidate in Tanzanian children aged 12-24 months. Malaria Journal, 8, 163.
   PubMed Web of Science ®Google Scholar
• Makobongo, M. O., Riding, G., Xu, H., Hirunpetcharat, C., Keough, D., de Jersey, J., Willadsen, P. & Good, M. F. (2003). The purine salvage enzyme hypoxanthine guanine xanthine phosphoribosyl transferase is a major target antigen for cell-mediated immunity to malaria. Proceedings of the National Academy of Sciences of the United States of America, 100, 2628–2633.
   PubMed Web of Science ®Google Scholar
• Malkin, E., Diemert, D. J., McArthur, J. H., Perreault, J. R., Miles, A. P., Giersing, B. K., Mullen, G. E., Orcutt, A., Muratova, O., Awkal, M., Zhou, H., Wang, J., Stowers, A., Long, C. A., Mahanty, S., Miller, L. H., Saul, A. & Durbin, A. P. (2005). Phase 1 clinical trial of apical membrane antigen 1: an asexual blood-stage vaccine for Plasmodium falci-parum malaria. Infection and Immunity, 73, 3677–3685.
   Google Scholar
• Malkin, E., Long, C. A., Stowers, A. W., Zou, L., Singh, S., Macdonald, N. J., Narum, D. L., Miles, A. P., Orcutt, A. C., Muratova, O., Moretz, S. E., Zhou, H., Diouf, A., Fay, M., Tierney, E., Leese, P., Mahanty, S., Miller, L. H., Saul, A. & Martin, L. B. (2007). Phase 1 study of two merozoite surface protein 1 (MSP1(42)) vaccines for Plasmodium falciparum malaria. PLoS Clinical Trials, 2, e12.
   Google Scholar
• Malkin, E., Hu, J., Li, Z., Chen, Z., Bi, X., Reed, Z., Dubovsky, F., Liu, J., Wang, Q., Pan, X., Chen, T., Giersing, B., Xu, Y., Kang, X., Gu, J., Shen, Q., Tucker, K., Tierney, E., Pan, W., Long, C. & Cao, Z. (2008). A Phase 1 trial of PfCP2.9: an AMA1/ MSP1 chimeric recombinant protein vaccine for Plasmodium falciparum malaria. Vaccine, 26, 6864–6873.
   PubMed Web of Science ®Google Scholar
• McIntosh, R. S., Shi, J., Jennings, R. M., Chappel, J. C., de Koning-Ward, T. F., Smith, T., Green, J., van Egmond, M., Leusen, J. H. W., Lazarou, M., van de Winkel, J., Jones, T. S., Crabb, B. S., Holder, A. A. & Pleass, R. J. (2007). The importance of human FcgammaRI in mediating protection to malaria. PLoS Pathogens, 3, e72.
   PubMed Web of Science ®Google Scholar
• Miura, K., Zhou, H., Diouf, A., Moretz, S. E., Fay, M. P., Miller, L. H., Martin, L. B., Pierce, M. A., Ellis, R. D., Mullen, G. E. D. & Long, C. A. (2009). Anti-apical-membrane-antigen-1 antibody is more effec-tive than anti-42-kilodalton-merozoite-surface-pro-tein-1 antibody in inhibiting Plasmodium falciparum growth, as determined by the in vitro growth inhibition assay. Clinical and Vaccine Immunology, 16, 963-968.
   Google Scholar
• Mlambo, G. & Kumar, N. (2008). Transgenic rodent Plasmodium berghei parasites as tools for assessment of functional immunogenicity and optimization of human malaria vaccines. Eukaryotic Cell, 7, 1875–1879.
   PubMed Web of Science ®Google Scholar
• Mlambo, G., Maciel, J. & Kumar, N. (2008). Murine model for assessment of Plasmodium falciparum transmission-blocking vaccine using transgenic Plasmodium berghei parasites expressing the target antigen Pfs25. Infection and Immunity, 76, 2018–2024.
   PubMed Web of Science ®Google Scholar
• Moorthy, V. S., Diggs, C., Ferro, S., Good, M. F., Herrera, S., Hill, A. V., Imoukhuede, E. B., Kumar, S., Loucq, C., Marsh, K., Ockenhouse, C. F., Richie, T. L. & Sauerwein, R. W. (2009). Report of a consultation on the optimization of clinical challenge trials for evaluation of candidate blood stage malaria vaccines, 18-19 March 2009, Bethesda, MD, USA. Vaccine, 27, 5719–5725.
   PubMedGoogle Scholar
• Mullen, G. E. D., Giersing, B. K., Ajose-Popoola, O., Davis, H. L., Kothe, C., Zhou, H., Aebig, J., Dobrescu, G., Saul, A. & Long, C. A. (2006). Enhancement of functional antibody responses to ANIA1-C1/Alhydrogel, a Plasmodium falciparum malaria vaccine, with CpG oligodeoxynucleotide. Vaccine, 24, 2497–2505.
   PubMed Web of Science ®Google Scholar
• Mullen, G. E. D., Ellis, R. D., Miura, K., Malkin, E., Nolan, C., Hay, M., Fay, M. P., Saul, A., Zhu, D., Rausch, K., Moretz, S., Zhou, H., Long, C. A., Miller, L. H. & Treanor, J. (2008). Phase 1 trial of ANIA1 -Cl/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS One, 3, e2940.
   Google Scholar
• Murhandarwati, E. E. H., Wang, L., Black, C. G., Nhan, D. H., Richie, T. L. & Coppel, R. L. (2009). Inhibitory antibodies specific for the 19-kilodalton fragment of merozoite surface protein 1 do not correlate with delayed appearance of infection with Plasmodium falciparum in semi-immune individuals in Viemam. Infection and Immunity, 77, 4510–4517.
   PubMed Web of Science ®Google Scholar
• Murhandarwati, E. E. H., Wang, L., de Silva, H. D., Ma, C., Plebanski, M., Black, C. G. & Coppel, R. L. (2010). Growth-inhibitory antibodies are not neces-sary for protective immunity to malaria infection. Infection and Immunity, 78, 680–687.
   PubMed Web of Science ®Google Scholar
• Ndungu, F. M., Cadman, E. T., Coulcher, J., Nduati, E., Couper, E., Macdonald, D. W., Ng, D. & Langhorne, J. (2009). Functional memory B cells and long-lived plasma cells are generated after a single Plasmodium chabaudi infection in mice. PLoS Pathogens, 5, e1000690.
   PubMed Web of Science ®Google Scholar
• Nebie, I., Diarra, A., Ouedraogo, A., Tiono, A. B., Konate, A. T., Gansane, A., Soulama, I., Cousens, S., Leroy, O. & Sirima, S. B. (2009). Humoral and cell-mediated immunity to MSP3 peptides in adults immunized with MSP3 in malaria endemic area, Burkina Faso. Parasite Immunology, 31, 474–480.
   PubMed Web of Science ®Google Scholar
• O'Donnell, R. A., Saul, A., Cowman, A. F. & Crabb, B. S. (2000). Functional conservation of the malaria vaccine antigen MSP-119 across distantly related Plasmodium species. Nature Medicine, 6, 91-95.
   Google Scholar
• Ockenhouse, C. F., Sun, P.-F., Lanar, D. E., Wellde, B. T., Hall, B. T., Kester, K., Stoute, J. A., Magill, A., Krzych, U., Farley, L., Wirtz, R A., Sadoff, J. C., Kaslow, D. C., Kumar, S., Church, LW. P., Crutcher, J. M., Wizel, B., Hoffman, S., Lalvani, A., Hill, A. V. S., Tine, J. A., Guito, K. P., de Taisne, C., Anders, R., Horii, T., Paoletti, E. & Ballou, W. R. (1998). Phase I/ Ha safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. Journal of Infectious Diseases, 177, 1664–1673.
   Google Scholar
• Ockenhouse, C. F., Angov, E., Kester, K. E., Diggs, C., Soisson, L., Cummings, J. F., Stewart, A. V., Palmer, D. R., Mahajan, B., Krzych, U., Tomieporth, N., Delchambre, M., Vanhandenhove, M., Ofori-Anyinam, O., Cohen, J., Lyon, J. A., Heppner, D. G. & The MSP-1 Working Group (2006). Phase I safety and immunogenicity trial of FMP1/ASO2A, a Plasmodium falciparum MSP-1 asexual blood stage vaccine. Vaccine. 24, 3009-3017.
   Google Scholar
• Og-utu, B. R., Apollo, O. J., McKinney, D., Okoth, W., Siangla, J., Dubovsky, F., Tucker, K., Waitumbi, J. N., Diggs, C., Wines, J., Malkin, E., Leach, A., Soisson, L. A., Milman, J. B., Otieno, L., Holland, C. A., Polhemus, M., Remich, S. A., Ockenhouse, C. F., Cohen, J., Ballou, W. R., Martin, S. K., Angov, E., Stewart, V. A., Lyon, J. A., Heppner Jr, D. G., Withers, M. R & The MSP-1 Vaccine Working Group (2009). Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in western Kenya. PLoS One, 4, e4708.
   Google Scholar
• Okiro, E. A., Hay, S. I., Gikandi, P. W., Sharif, S. K., Noor, A. M., Peshu, N., Marsh, K. & Snow, R. W. (2007). The decline in paediatric malaria admissions on the coast of Kenya. Malaria Journal, 6, 151.
   PubMed Web of Science ®Google Scholar
• Oxford, J. S. (2008). The end of the beginning: vaccines for the next 25 years. Vaccine, 26, 6179–6182.
   PubMed Web of Science ®Google Scholar
• Persson, C., Oliveira, G. A., Sultan, A. A., Bhanot, P., Nussenzweig, V. & Nardin, E. (2002). Cutting edge: a new tool to evaluate human pre-erythrocytic malaria vaccines: rodent parasites bearing a hybrid Plasmodium falciparum circumsporozoite protein. Journal of Immunology, 169, 6681–6685.
   PubMed Web of Science ®Google Scholar
• Pichichero, M. E. (2008). Improving vaccine delivery using novel adjuvant systems. Human Vaccines, 4, 262–270.
   PubMed Web of Science ®Google Scholar
• Pichyangkul, S., Tongtawe, P., Kum-Arb, U., Yongvanitchit, K., Gettayacamin, M., Hollingdale, M. R., Limsalakpetch, A., Stewart, V. A., Lanar, D. E., Dutta, S., Angov, E., Ware, L. A., Bergmann-Leimer, E. S., House, B., Voss, G., Dubois, M. C., Cohen, J. D., Fukuda, M. M., Heppner, D. G. & Miller, R S. (2009). Evaluation of the safety and immunogenicity of Plasmodium falciparum apical membrane antigen 1, merozoite surface protein 1 or RTS,S vaccines with adjuvant system A502A admi-nistered alone or concurrently in rhesus monkeys. Vaccine, 28, 452–462.
   PubMed Web of Science ®Google Scholar
• Pierce, M. A., Ellis, R. D., Martin, L. B., Malkin, E., Tierney, E., Miura, K., Fay, M. P., Marjason, J., Elliott, S. L., Mullen, G. E., Rausch, K., Zhu, D., Long, C. A. & Miller, L. H. (2010). Phase 1 safety and immunogenicity trial of the Plasmodium falci-parum blood-stage malaria vaccine AMA1 -C1/ISA 720 in Australian adults. Vaccine, 28, 2236–2242.
   PubMed Web of Science ®Google Scholar
• Pinzon-Charry, A. & Good, M. F. (2008). Malaria vaccines: the case for a whole-organism approach. Expert Opinion on Biological Therapy, 8, 441–448.
   PubMed Web of Science ®Google Scholar
• Pleass, R. J. (2009). Fc-receptors and immunity to malaria: from models to vaccines. Parasite Immunology, 31, 529–538.
   PubMed Web of Science ®Google Scholar
• Polhemus, M. E., Magill, A. J., Cummings, J. F., Kester, K. E., Ockenhouse, C. F., Lanar, D. E., Dutta, S., Barbosa, A., Soisson, L., Diggs, C. L., Robinson, S. A., Haynes, J. D., Stewart, V. A., Ware, L. A., Brando, C., Krzych, U., Bowden, R. A., Cohen, J. D., Dubois, M. C., Ofori-Anyinam, O., De-Kock, E., Ballou, W. R. & Heppner D. G. Jr (2007). Phase I dose escalation safety and immuno-genicity trial of Plasmodium falciparum apical mem-brane protein (AMA-1) FMP2.1, adjuvanted with A502A, in malaria-naive adults at the Walter Reed Army Institute of Research. Vaccine, 25, 4203–4212.
   PubMed Web of Science ®Google Scholar
• Pombo, D. J., Lawrence, G., Hirunpetcharat, C., Rzepczyk, C., Bryden, M., Cloonan, N., Anderson, K., Mahakunkijcharoen, Y., Martin, L. B., Wilson, D., Elliott, S., Elliott, S., Eisen, D. P., Weinberg, J. B., Saul, A. & Good, M. F. (2002). Immunity to malaria after administration of ultra-low doses of red cells infected with Plasmodium falciparum. Lancet, 360, 610–617.
   PubMed Web of Science ®Google Scholar
• Ramjanee, S., Robertson, J. S., Franke-Fayard, B., Sinha, R., Waters, A. P., Janse, C. J., Wu, Y., Blagborough, A. M., Saul, A. & Sinden, R. E. (2007). The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials. Vaccine, 25, 886–894.
   PubMed Web of Science ®Google Scholar
• Reed, S. G., Bertholet, S., Coler, R N. & Friede, M. (2009). New horizons in adjuvants for vaccine development. Trends in Immunology, 30, 23–32.
   PubMed Web of Science ®Google Scholar
• Remarque, E. J., Faber, B. W., Kocken, C. H. M. & Thomas, A. W. (2008). Apical membrane antigen 1: a malaria vaccine candidate in review. Trends in Parasitology, 24, 74–84.
   PubMed Web of Science ®Google Scholar
• Rerks-Ngarm, S., Pitisuttithum, P., Nitayaphan, S., Kaewkungwal, J., Chiu, J., Paris, R, Premsri, N., Namwat, C., de Souza, M., Adams, E., Benenson, M., Gurunathan, S., Tartaglia, J., McNeil, J. G., Francis, D. P., Stablein, D., Birx, D. L., Chunsuttiwat, S., Khamboonruang, C., Thongcharoen, P., Robb, M. L., Michael, N. L., Kunasol, P. & Kim, J. H. (2009). Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. New England Journal of Medicine, 361, 2209–2220.
   PubMed Web of Science ®Google Scholar
• Reyes-Sandoval, A., Pearson, F. E., Todryk, S. & Ewer, K. (2009). Potency assays for novel T-cell-inducing vaccines against malaria. Current Opinion in Molecular Therapeutics, 11, 72–80.
   PubMed Web of Science ®Google Scholar
• Roestenberg, M., Remarque, E., de Jonge, E., Hermsen, R., Blythman, H., Leroy, O., Imoukhuede, E., Jepsen, S., Ofori-Anyinarn, O., Faber, B., Kocken, C. H. M., Arnold, M., Walraven, V., Teelen, K., Roeffen, W., de Mast, Q., Ballou, W. R., Cohen, J., Dubois, M. C., Ascarateil, S., van der Ven, A., Thomas, A. & Sauerwein, R. (2008). Safety and immunogenicity of a recombinant Plasmodium falciparum AMA1 malaria vaccine adjuvanted with Alhydrogel, Montanide ISA 720 or A502. PLoS One, 3, e3960.
   Google Scholar
• Roestenberg, M., McCall, M., Hopman, J., Wiersma, J., Luty, A. J. F., van Gemert, G. J., van de Vegte-Bolmer, M., van Schaijk, B., Teelen, K., Arens, T., Spaarman, L., de Mast, Q., Roeffen, W., Snounou, G., Renia, L., van der Ven, A., Hermsen, C. C. & Sauerwein, R. (2009). Protection against a malaria challenge by sporozoite inoculation. New England Journal of Medicine, 361, 468–477.
   PubMed Web of Science ®Google Scholar
• Sagara, I., Dicko, A., Ellis, R. D., Fay, M. P., Diawara, S. I., Assadou, M. H., Sissoko, M. S., Kone, M., Diallo, A. I., Saye, R., Guindo, M. A., Kante, O., Niambele, M. B., Miura, K., Mullen, G. E. D., Pierce, M., Martin, L. B., Dolo, A., Diallo, D. A., Doumbo, O. K., Miller, L. H. & Saul, A. (2009a). A randomized controlled Phase 2 trial of the blood stage AMA1-C1/Alhydrogel malaria vaccine in chil-dren in Mali. Vaccine, 27, 3090–3098.
   PubMed Web of Science ®Google Scholar
• Sagara, I., Ellis, R. D., Dicko, A., Niambele, M. B., Kamate, B., Guindo, O., Sissoko, M. S., Fay, M. P., Guindo, M. A., Kante, O., Saye, R., Miura, K., Long, C., Mullen, G. E. D., Pierce, M., Martin, L. B., Rausch, K., Dolo, A., Diallo, D. A., Miller, L. H. & Doumbo, O. K. (2009b). A randomized and controlled Phase 1 study of the safety and immuno-genicity of the AMAl-C1/Alhydrogel CPG 7909 vaccine for Plasmodium falciparum malaria in semi-immune Malian adults. Vaccine, 27, 7292–7298.
   PubMed Web of Science ®Google Scholar
• Sanderson, F., Andrews, L., Douglas, A. D., Hunt-Cooke, A., Bejon, P. & Hill, A. V. S. (2008). Blood-stage challenge for malaria vaccine efficacy trials: a pilot study with discussion of safety and potential value. American Journal of Tropical Medicine and Hygiene, 78, 878–883.
   PubMed Web of Science ®Google Scholar
• Saul, A., Lawrence, G., Smillie, A., Rzepczyk, C. M., Reed, C., Taylor, D., Anderson, K., Stowers, A., Kemp, R, Allworth, A., Anders, R F., Brown, G. V., Pye, D., Schoofs, P., Irving, D. O., Dyer, S. L., Woodrow, G. C., Briggs, W. R, Reber, R. & Sturchler, D. (1999). Human Phase I vaccine trials of 3 recombinant asexual stage malaria antigens with Montanide I5A720 adjuvant. Vaccine, 17, 3145–3159.
   PubMed Web of Science ®Google Scholar
• Saul, A., Lawrence, G., Allworth, A., Elliott, S., Anderson, K., Rzepczyk, C., Martin, L. B., Taylor, D., Eisen, D. P., Irving, D. O., Pye, D., Crewther, P. E., Hodder, A. N., Murphy, V. J. & Anders, R. F. (2005). A human Phase 1 vaccine clinical trial of the Plasmodium falciparum malaria vaccine candidate apical membrane antigen 1 in Montanide I5A720 adjuvant. Vaccine, 23, 3076–3083.
   PubMed Web of Science ®Google Scholar
• Schofield, L., Hewitt, M. C., Evans, K., Siomos, M.-A. & Seeberger, P. H. (2002). Synthetic GPI as a candidate anti-toxic vaccine in a model of malaria. Nature, 418, 785–789.
   PubMed Web of Science ®Google Scholar
• Silvie, O., Franetich, J.-F., Charrin, S., Mueller, M. S., Siau, A., Bodescot, M., Rubinstein, E., Hannoun, L., Charoenvit, Y., Kocken, C. H., Thomas, A. W., van Gemert, G.-J., Sauerwein, R. W., Blackman, M. J., Anders, R. F., Pluschke, G. & Mazier, D. (2004). A role for apical membrane antigen 1 during invasion of hepatocytes by Plasmodium falciparum sporozoites. Journal of Biological Chemistry, 279, 9490–9496.
   PubMed Web of Science ®Google Scholar
• Singh, S., Alam, M. M., Pal-Bhowmick, I., Brzostowski, J. A. & Chimis, C. E. (2010). Distinct external signals trigger sequential release of apical organelles during erythrocyte invasion by malaria parasites. PLoS Pathogens, 6, e1000746.
   PubMed Web of Science ®Google Scholar
• Sirima, S. B., Nébié, I., Ouédraogo, A., Tiono, A. B., Konaté, A. T., Gansane, A., Dermé, A. I., Diarra, A., Ouédraogo, A., Soulama, I., Cuzzin-Ouattara, N., Cousens, S. & Leroy, O. (2007). Safety and immunogenicity of the Plasmodium falciparum mer-ozoite surface protein-3 long synthetic peptide (MSP3-LSP) malaria vaccine in healthy, semi-immune adult males in Burkina Faso, West Africa. Vaccine, 25, 2723–2732.
   PubMed Web of Science ®Google Scholar
• Sirima, S. B., Tiono, A. B., Ouédraogo, A., Diarra, A., Ouédraogo, A. L., Yaro, J. B., Ouédraogo, E., Gansané, A., Bougouma, E. C., Konaté, A. T., Kaboré, Y., Traoré, A., Roma, C., Soulama, I., Luty, A. J., Cousens, S. & Nébié, I. (2009). Safety and immunogenicity of the malaria vaccine candidate MSP3 long synthetic peptide in 12-24 months-old Burkinabe children. PLoS One, 4, e7549.
   PubMed Web of Science ®Google Scholar
• Spring, M. D., Cummings, J. F., Ockenhouse, C. F., Dutta, S., Reidler, R., Angov, E., Bergmann-Leimer, E., Stewart, V. A., Bittner, S., Juompan, L., Kortepeter, M. G., Nielsen, R., Krzych, U., Tierney, E., Ware, L. A., Dowler, M., Hermsen, C. C., Sauerwein, R. W., de Vlas, S. J., Ofori-Anyinam, O., Lanar, D. E., Williams, J. L., Kester, K. E., Tucker, K., Shi, M., Malkin, E., Long, C., Diggs, C. L., Soisson, L., Dubois, M.-C., Ballou, W. R., Cohen, J. & Heppner D. G. Jr (2009). Phase 1/2a study of the malaria vaccine candidate apical membrane antigen-1 (AMA-1) administered in adjuvant system A501B or A502A. PLoS One, 4, e5254.
   PubMed Web of Science ®Google Scholar
• Stahl, H. D., Bianco, A. E., Crewther, P. E., Anders, R. F., Kyne, A. P., Coppel, R L., Mitchell, G. F., Kemp, D. J. & Brown, G. V. (1986). Sorting large numbers of clones expressing Plasmodium falciparum antigens in Escherichia coli by differential antibody screening. Molecular Biology and Medicine, 3, 351–368.
   PubMedGoogle Scholar
• Stoute, J. A., Gombe, J., Withers, M. R., Siangla, J., McKinney, D., Onyango, M., Cummings, J. F., Milman, J., Tucker, K., Soisson, L., Stewart, V. A., Lyon, J. A., Angov, E., Leach, A., Cohen, J., Kester, K. E., Ockenhouse, C. F., Holland, C. A., Diggs, C. L., Wines, J. & Heppner D. G. Jr (2007). Phase 1 randomized double-blind safety and immunogenicity trial of Plasmodium falciparum malaria merozoite surface protein FMP1 vaccine, adjuvanted with ASO2A, in adults in western Kenya. Vaccine, 25, 176–184.
   PubMed Web of Science ®Google Scholar
• Suhrbier, A., Holder, A. A., Wiser, M. F., Nicholas, J. & Sinden, R. E. (1989). Expression of the precursor of the major merozoite surface antigens during the hepatic stage of malaria. American Journal of Tropical Medicine and Hygiene, 40, 351–355.
   PubMed Web of Science ®Google Scholar
• Szarfman, A., Walliker, D., McBride, J. S., Lyon, J. A., Quakyi, I. A. & Carter, R. (1988). Allelic forms of gp195, a major blood-stage antigen of Plasmodium falciparum, are expressed in liver stages. Journal of Immunology, 167, 231–236.
   Google Scholar
• Tebo, A. E., Kremsner, P. G. & Luty, A. J. F. (2002). Fcy receptor-mediated phagocytosis of Plasmodium falciparum-infected erythrocytes in vitro. Clinical and Experimental Immunology, 130, 300-306.
   Google Scholar
• Theisen, M., Soe, S., Brunstedt, K., Follmann, F., Bredmose, L., Israelsen, H., Madsen, S. M. & Druilhe, P. (2004). A Plasmodium falciparum GLURP—MSP3 chimeric protein; expression in Lactococcus lactis, immunogenicity and induction of biologically active antibodies. Vaccine, 22, 1188–1198.
   PubMed Web of Science ®Google Scholar
• Thera, M. A., Doumbo, O. K., Coulibaly, D., Diallo, D. A., Sagara, I., Dicko, A., Diemert, D. J., Heppner Jr, D. G., Stewart, V. A., Angov, E., Soisson, L., Leach, A., Tucker, K., Lyke, K.E. & Plowe, C. V. (2006). Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a Phase I randomized trial. PLoS Clinical Trials, 1, e34.
   Google Scholar
• Thera, M. A., Doumbo, O. K., Coulibaly, D., Diallo, D. A., Kone, A. K., Guindo, A. B., Traore, K., Dicko, A., Sagara, I., Sissoko, M. S., Baby, M., Sissoko, M., Diarra, I., Niangaly, A., Dolo, A., Daou, M., Diawara, S. I., Heppner, D. G., Stewart, V. A., Angov, E., Bergmann-Leitner, E. S., Lanar, D. E., Dutta, S., Soisson, L., Diggs, C. L., Leach, A., Owusu, A., Dubois, M. C., Cohen, J., Nixon, J. N., Gregson, A., Takala, S. L., Lyke, K. E. & Plowe, C. V. (2008). Safety and immunogenicity of an A1\4A-1 malaria vaccine in Malian adults: results of a Phase 1 randomized controlled trial. PLoS One, 3, el465.
   Google Scholar
• Thompson, F. M., Porter, D. W., Okitsu, S. L., Westerfeld, N., Vogel, D., Todryk, S., Poulton, I., Correa, S., Hutchings, C., Berthoud, T., Dunachie, S., Andrews, L., Williams, J. L., Sinden, R., Gilbert, S. C., Pluschke, G., Zurbriggen, R. & Hill, A. V. S. (2008). Evidence of blood stage efficacy with a virosomal malaria vaccine in a Phase ha clinical trial. PLoS One, 3, el493.
   Google Scholar
• Traore, B., Koné, Y., Doumbo, S., Doumtabé, D., Traoré, A., Crompton, P. D., Mircetic, M., Huang, C.-Y., Kayentao, K., Dicko, A., Sagara, I., Ellis, R. D., Miura, K., Guindo, A., Miller, L. H., Doumbo, O. K. & Pierce, S. K. (2009). The TLR9 agonist CpG fails to enhance the acquisition of Plasmodium falciparum-specific memory B cells in semi-immune adults in Mali. Vaccine, 27, 7299–7303.
   PubMed Web of Science ®Google Scholar
• Treeck, M., Zacherl, S., Herrmann, S., Cabrera, A., Kono, M., Struck, N. S., Engelberg, K., Haase, S., Frischknecht, F., Miura, K., Spielmann, T. & Gilberger, T. W. (2009). Functional analysis of the leading malaria vaccine candidate AMA-1 reveals an essential role for the cytoplasmic domain in the invasion process. PLoS Pathogens, 5, el 000322.
   Google Scholar
• Triglia, T., Healer, J., Caruana, S. R., Hodder, A. N., Anders, R. F., Crabb, B. S. & Cowman, A. F. (2000). Apical membrane antigen 1 plays a central role in erythrocyte invasion by Plasmodium species. Molecular Microbiology, 38, 706–718.
   PubMed Web of Science ®Google Scholar
• Van der Heyde, H. C., Huszar, D., Woodhouse, C., Manning, D. D. & Weidanz, W. P. (1994). The resolution of acute malaria in a definitive model of B cell deficiency, the JHD mouse. Journal of Immunology, 152, 4557-4562.
   Google Scholar
• Vargas-Serrato, E., Barnwell, J. W., Ingravallo, P., Perler, F. B. & Galinski, M. R. (2002). Merozoite surface protein-9 of Plasmodium vivax and related simian malaria parasites is orthologous to p101/ ABRA of P. falciparum. Molecular and Biochemical Parasitology, 120, 41-52.
   Google Scholar
• Wang, Q., Brown, S., Roos, D. S., Nussenzweig, V. & Bhanot, P. (2004). Transcriptome of axenic liver stages of Plasmodium yoelii. Molecular and Biochemical Parasitology, 137, 161–168.
   PubMed Web of Science ®Google Scholar
• Webster, D. P., Dunachie, S., Vuola, J. M., Berthoud, T., Keating, S., Laidlaw, S. M., McConkey, S. J., Poulton, I., Andrews, L., Andersen, R. F., Bejon, P., Butcher, G., Sinden, R., Skinner, M. A., Gilbert, S. C. & Hill, A. V. S. (2005). Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proceedings of the National Academy of Sciences of the United States of America, 102, 4836–4841.
   PubMed Web of Science ®Google Scholar
• Weiss, G. E., Crompton, P. D., Li, S., Walsh, L. A., Moir, S., Traore, B., Kayentao, K., Ongoiba, A., Doumbo, O. K. & Pierce, S. K. (2009). Atypical memory B cells are greatly expanded in individuals living in a malaria-endemic area. Journal of Immunology, 183, 2176–2182.
   PubMed Web of Science ®Google Scholar
• Wipasa, J., Hirunpetcharat, C., Mahakunkijcharoen, Y., Xu, H., Elliott, S. & Good, M. F. (2002). Identification of T cell epitopes on the 33-kDa fragment of Plasmodium yoelii merozoite surface protein 1 and their antibody-independent protective role in immunity to blood stage malaria. Journal of Immunology, 169, 944-951.
   Google Scholar
• World Health Organization (2008). World Malaria Report 2008. Document WHO/HTM/GMP/2008.1. Geneva: WHO.
   Google Scholar
• Wykes, M. N., Zhou, Y.-H., Liu, X. Q. & Good, M. F. (2005). Plasmodium yoelii can ablate vaccine-induced long-term protection in mice. Journal of Immunology, 175, 2510-2516.
   Google Scholar
• Xu, H., Hodder, A. N., Yan, H., Crewther, P. E., Anders, R. F. & Good, M. F. (2000). CD4 + T cells acting independently of antibody contribute to protective immunity to Plasmodium chabaudi infec-tion after apical membrane antigen 1 immunization. Journal of Immunology, 165, 389–396.
   PubMed Web of Science ®Google Scholar
• Yoneto, T., Waki, S., Takai, T., Tagawa, Y., Iwakura, Y., Mizuguchi, J., Nariuchi, H. & Yoshimoto, T. (2001). A critical role of Fc receptor-mediated antibody-dependent phagocytosis in the host resis-tance to blood-stage Plasmodium berghei XAT infec-tion. Journal of Immunology, 166, 6236–6241.
   PubMed Web of Science ®Google Scholar